334 related articles for article (PubMed ID: 21779467)
1. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Ossovskaya V; Koo IC; Kaldjian EP; Alvares C; Sherman BM
Genes Cancer; 2010 Aug; 1(8):812-21. PubMed ID: 21779467
[TBL] [Abstract][Full Text] [Related]
2. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
3. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
4. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
[TBL] [Abstract][Full Text] [Related]
6. Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer.
Sun X; Tang H; Chen Y; Chen Z; Hu Z; Cui Z; Tao Y; Yuan J; Fu Y; Zhuang Z; He Q; Li Q; Xu X; Wan X; Jiang Y; Mao Z
Nat Cancer; 2023 May; 4(5):716-733. PubMed ID: 37012401
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
8. A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.
Li D; Bi FF; Chen NN; Cao JM; Sun WP; Zhou YM; Li CY; Yang Q
Cell Cycle; 2014; 13(21):3442-9. PubMed ID: 25485588
[TBL] [Abstract][Full Text] [Related]
9. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.
Krishnan A; Spegg V; Dettwiler S; Schraml P; Moch H; Dedes K; Varga Z; Altmeyer M
Mod Pathol; 2023 Jul; 36(7):100167. PubMed ID: 36990278
[TBL] [Abstract][Full Text] [Related]
11. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Gan A; Green AR; Nolan CC; Martin S; Deen S
Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of quinazolin-4(3
Chang X; Sun D; Shi D; Wang G; Chen Y; Zhang K; Tan H; Liu J; Liu B; Ouyang L
Acta Pharm Sin B; 2021 Jan; 11(1):156-180. PubMed ID: 33532187
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
Anders CK; Winer EP; Ford JM; Dent R; Silver DP; Sledge GW; Carey LA
Clin Cancer Res; 2010 Oct; 16(19):4702-10. PubMed ID: 20858840
[TBL] [Abstract][Full Text] [Related]
15. PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.
Stanley J; Klepczyk L; Keene K; Wei S; Li Y; Forero A; Grizzle W; Wielgos M; Brazelton J; LoBuglio AF; Yang ES
Breast Cancer Res Treat; 2015 Apr; 150(3):569-79. PubMed ID: 25833211
[TBL] [Abstract][Full Text] [Related]
16. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Comen EA; Robson M
Cancer J; 2010; 16(1):48-52. PubMed ID: 20164690
[TBL] [Abstract][Full Text] [Related]
18. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
Papadimitriou M; Mountzios G; Papadimitriou CA
Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
[TBL] [Abstract][Full Text] [Related]
19. Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
Song D; He H; Sinha I; Hases L; Yan F; Archer A; Haldosen LA; Zhao C; Williams C
Cancer Lett; 2021 May; 506():23-34. PubMed ID: 33652085
[TBL] [Abstract][Full Text] [Related]
20. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
Sang M; Meng L; Ma C; Liu S; Sang M; Chang S; Liu F; Lian Y; Geng C
Biomed Pharmacother; 2019 Mar; 111():169-177. PubMed ID: 30580238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]